Cargando…

Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists

Direct oral factor Xa inhibitors (DXIs) are approved for use in adult patients with non-valvular heart disease for stroke prevention, and the treatment/prevention of venous thromboembolism (VTE). Recent pediatric clinical trials have demonstrated safety and efficacy of direct oral anticoagulants (DO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodriguez, Vilmarie, Stanek, Joseph, Kerlin, Bryce A., Dunn, Amy L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Manuscript
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921759/ https://www.ncbi.nlm.nih.gov/pubmed/35275498 http://dx.doi.org/10.1177/10760296221078842

Ejemplares similares

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
por: Mehrotra, Siddharth, et al.
Publicado: (2022)

Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
por: Bradshaw, Paige Garber, et al.
Publicado: (2022)

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
por: Stevens, Victoria M., et al.
Publicado: (2021)

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis
por: Costa, Olivia S., et al.
Publicado: (2022)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
por: Heo, Young-A
Publicado: (2018)

Correction to: Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA
por: Heo, Young-A
Publicado: (2018)

Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop
por: Taune, Viktor, et al.
Publicado: (2022)

Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage
por: Troyer, Camille, et al.
Publicado: (2022)

Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra
por: Brinkman, Herm Jan M., et al.
Publicado: (2022)

Heparin Insensitivity and Thrombotic Risk Associated With Sequential Uses of Prothrombin Complex Concentrate and Andexanet Alfa for Apixaban Reversal During Acute Type A Aortic Dissection Repair: A Case Report
por: Brenner, Brian, et al.
Publicado: (2022)

Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products
por: Castillo, Renee, et al.
Publicado: (2020)

Correction to: Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products
por: Castillo, Renee, et al.
Publicado: (2020)

A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding
por: Jaspers, Tessa, et al.
Publicado: (2021)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
por: Kaatz, Scott, et al.
Publicado: (2017)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation
por: Lu, Genmin, et al.
Publicado: (2020)

Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Institutional Experience of Using Andexanet Alfa
por: Khadka, Sushmita, et al.
Publicado: (2020)

Correction to: Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Activated Partial Thromboplastin Time or Prothrombin Time Prolongation During Rivaroxaban Administration: Clinical Risk Factors and Outcomes Analysis
por: Yuan, Yao, et al.
Publicado: (2023)

Reversibility of Apixaban Anticoagulation with a Four‐Factor Prothrombin Complex Concentrate in Healthy Volunteers
por: Nagalla, S, et al.
Publicado: (2016)

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
por: Hu, Tiffany Y, et al.
Publicado: (2016)

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
por: Nederpelt, Charlie J., et al.
Publicado: (2020)

Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study
por: Rauch, Sebastian, et al.
Publicado: (2022)

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban
por: Benz, Alexander P., et al.
Publicado: (2022)

Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
por: Watson, C. James, et al.
Publicado: (2019)

Successful use of an antithrombin for heparin resistance with andexanet alfa
por: Honda, Jun, et al.
Publicado: (2023)

Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
por: Sutton, S. Scott, et al.
Publicado: (2023)

Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study
por: Dobesh, Paul P., et al.
Publicado: (2023)

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Andexanet-Alfa-Associated Heparin Resistance in the Context of Hemorrhagic Stroke
por: Müther, Michael, et al.
Publicado: (2022)

Andexanet alfa — Recommendations for clinical use. Multidisciplinary experts’ standpoint
por: Kubica, Jacek, et al.
Publicado: (2023)

Correction to: Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
por: Sutton, S. Scott, et al.
Publicado: (2023)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Four‐factor prothrombin complex concentrate reverses apixaban‐associated bleeding in a rabbit model of acute hemorrhage
por: Herzog, E., et al.
Publicado: (2015)

Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects
por: Ansell, Jack, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7lgt5cbujkpspi0lkobarvrpjg